Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.57 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332934 | 0.85 | PTGS1 (0.61) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL5463061 | 0.85 | PTGS1 (0.61) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL16055994 | 0.85 | PTGS1 (0.53) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL316091 | 0.84 | PTGS1 (0.60) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL19549046 | 0.84 | PTGS1 (0.60) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL235440 | 0.84 | PTGS1 (0.56) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL3501491 | 0.83 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL8840196 | 0.83 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL993262 | 0.83 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL3388582 | 0.82 | PTGS1 (0.57) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224633-B2 | Kit for treating sepsis and/or any systemic (SIRS) or damaging cellular hyperinflammation | SERENITE-FORCEVILLE (FR) | 2022-01-18 | — | — | US | claimed |
| WO-2021216581-A1 | METHOD OF TREATING AND PREVENTING CORONAVIRUS DISEASE 19 (COVID-19) USING A SELENIUM ADMINISTRATION | GHOWEBA MOHAMED SAMIR ELSAYED (US) | 2021-10-28 | — | — | WO | claimed |
| US-20210322464-A1 | METHOD OF TREATING AND PREVENTING CORONAVIRUS DISEASE 19 (COVID-19) USING A SELENIUM ADMINISTRATION | GHOWEBA MOHAMED SAMIR ELSAYED (US) | 2021-10-21 | — | — | US | claimed |
| US-20180185443-A1 | KIT FOR TREATING SEPSIS AND/OR ANY SYSTEMIC (SIRS) OR DAMAGING CELLULAR HYPERINFLAMMATION | SERENITE-FORCEVILLE (FR) | 2018-07-05 | — | — | US | claimed |
| EP-3313414-A1 | KIT FOR TREATING SEPSIS AND/OR ANY SYSTEMIC (SIRS) OR DAMAGING CELLULAR HYPERINFLAMMATION | Sérénité-Forceville (FR) | 2018-05-02 | — | — | EP | claimed |
| WO-2016207577-A1 | KIT FOR TREATING SEPSIS AND/OR ANY SYSTEMIC (SIRS) OR DAMAGING CELLULAR HYPERINFLAMMATION | SÉRÉNITÉ-FORCEVILLE (FR) | 2016-12-29 | — | — | WO | claimed |
| WO-2005023274-A1 | TREATMENT AND PREVENTION OF INFLAMMATORY DISEASE AND MITOCHONDRIAL DYSFUNCTION WITH HIGH DOSE SELENIUM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-03-17 | — | — | WO | claimed |
| US-6844012-B1 | Use of selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing said treatment | Forceville, Xavier (FR) | 2005-01-18 | — | — | US | claimed |
| EP-1107767-A2 | USE OF SELENIUM FOR TREATING PATIENTS SUFFERING FROM SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS), AND COMPOSITION FOR IMPLEMENTING SAID TREATMENT | Forceville, Xavier (FR) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012101-A2 | USE OF SELENIUM FOR TREATING PATIENTS SUFFERING FROM SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS), AND COMPOSITION FOR IMPLEMENTING SAID TREATMENT | FORCEVILLE XAVIER (FR) | 2000-03-09 | — | — | WO | claimed |
| WO-1993021304-A1 | METHOD FOR THE INHIBITION OF THE PROLIFERATION OF CANCER CELLS IN A TUMOR | THE OHIO STATE UNIVERSITY (US) | 1993-10-28 | — | — | WO | claimed |
| US-5118624-A | Administering to eukaryotic cells containing elongatin factor wherein the effect varies according to the concentration | THE OHIO STATE UNIVERSITY (US) | 1992-06-02 | — | — | US | claimed |
| US-5104852-A | Administering selenodiglutathione, selenodicysteine or selenodimethionone to the center of a tumor from where it diffuses outwardly | THE OHIO STATE UNIVERSITY (US) | 1992-04-14 | — | — | US | claimed |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025217207-A1 | SYSTEMS AND METHODS FOR EVALUATION OF GASTROINTESTINAL DISEASE AND APPLICATIONS THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12339286-B2 | Metal-reducing enzymatic tag for optical and electron microscopy | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-5118624-A | Administering to eukaryotic cells containing elongatin factor wherein the effect varies according to the concentration | THE OHIO STATE UNIVERSITY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5104852-A | Administering selenodiglutathione, selenodicysteine or selenodimethionone to the center of a tumor from where it diffuses outwardly | THE OHIO STATE UNIVERSITY (US) | 1992-04-14 | — | — | US | disclosed |
| US-5104852-A | Administering selenodiglutathione, selenodicysteine or selenodimethionone to the center of a tumor from where it diffuses outwardly | THE OHIO STATE UNIVERSITY (US) | 1992-04-14 | — | — | US | disclosed |
| US-4865840-A | Topical compositions containing selenoamino acids for the prevention of ultraviolet radiation-induced skin damage | MITSUBISHI GAS CHEMICAL COMPANY, INC. | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | PTGS1 2746/4885GSTK1 3533/4885GLO1 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.